CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX Account Payables

Amounts the company owes suppliers for goods and services received.

CytomX Therapeutics, Inc.NASDAQ: CTMX

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 395.7% from a year ago

Account payables stood at $1.37M at the end of Q1 FY2026, up 395.7% from a year earlier and up 5.1% from the prior quarter. Over 3 fiscal years it compounded at -22.6% a year.

Context

  • Account payables amounted to 0.4% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +395.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.37M+5.1% QoQ
Last fiscal yearDec 2025
$1.3M+19.6% YoY
Year agoMar 2025
$276K+395.7% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+395.7%——
1 year+19.6%——
3-year CAGR-22.6%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
1.3M USD
Year-over-year change
+19.6%
4-year CAGR
-17.6%

Account Payables vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's Mar 2026 account payables of $1.37M is the lowest of the 10 companies compared; the peer median is $5.49M.
  • Its year-over-year change of +395.7% is the 2nd highest of 10, against a peer median of -31.8%.
  • Account payables amounts to 0.4% of total assets for CTMX, versus a peer median of 2.3%.
CTMX Competitors Peer median
Account Payables for CTMX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZYMEZymeworks Inc.Sep 2026$131.86M +10004.4%-17.6%11.2%
NRIXNurix Therapeutics, Inc.Aug 2026$32.98M +283.1%+30.3%2.8%
XNCRXencor, Inc.Jun 2026$12.65M -31.8%+2.4%1.7%
CLDXCelldex Therapeutics, Inc.Sep 2026$11.24M +163.4%-29.3%1.6%
STROSutro Biopharma, Inc.Mar 2026$5.49M -32.9%+16.4%2.3%
ADCTADC Therapeutics S.A.Mar 2026$5.3M -66.0%-9.4%1.8%
PYXSPyxis Oncology, Inc.Mar 2026$4.99M +75.3%+15.3%7.8%
MGNXMacroGenics, Inc.Mar 2026$4.29M -35.2%-0.8%2.0%
ADAGAdagene Inc.Dec 2025$2.88M -32.0%-7.7%3.7%
CTMXCytomX Therapeutics, Inc.Mar 2026$1.37M +395.7%-22.6%0.4%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CTMX) $5.49M-31.8%-0.8%2.3%

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents205.53M193.65M17.17M38.05M12.67M
Short-term Investments99.7M0157.34M62.57M124.39M
Net Receivables790K35.99M3.43M3.1M2.01M
Inventory00000
Other Current Assets07.47M5M3.58M4.86M
Total Current Assets310.3M237.1M182.94M107.31M143.92M
Property, Plant & Equipment (Net)25.32M21.02M16.18M10.6M4.7M
Goodwill949K949K949K949K949K
Intangible Assets1.02M875K729K583K438K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.82M944K1M1.09M1.56M
Total Non-current Assets29.11M23.79M18.86M13.23M7.65M
Total Assets339.41M260.89M201.79M120.53M151.57M
Account Payables2.82M2.81M1.46M1.09M1.3M
Short-term Debt00004.24M
Tax Payables00000
Deferred Revenue40.82M121.27M132.27M67.2M26.88M
Other Current Liabilities009.44M05.99M
Total Current Liabilities77.87M152.61M155.91M85.77M46.62M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)243.94M180.06M80.05M26.86M1.59M
Other Non-current Liabilities003.89M4.12M4.35M
Total Non-current Liabilities262M194.03M93.33M35.22M5.94M
Total Liabilities339.87M346.64M249.24M120.99M52.56M
Common Stock1K1K1K1K2K
Retained Earnings(623.56M)(722.88M)(723.45M)(691.58M)(711.95M)
Accumulated OCI(242K)10K95K27K111K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(459K)(85.75M)(47.45M)(456K)99.01M
Total Debt21.67M18.06M13.97M9.39M4.24M
Net Debt(183.86M)(175.59M)(3.2M)(28.67M)(8.43M)

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.